This study is testing a new treatment for people with HIV-1, which is a virus that weakens the immune system. The usual treatment for HIV-1 involves taking several medicines daily. The study is checking if a new treatment, combining two medicines, islatravir and ulonivirine, works just as well when taken once a week.

Key Points:

• This study involves taking medicine once a week, which could be easier than the usual daily doses.
• Participants should not have taken any HIV-1 medicines before joining this study.
• The study aims to ensure the new treatment is safe and is tolerated well by participants.

To join, participants must have a certain level of HIV-1 in their blood, and they should not have other conditions like HIV-2 or active hepatitis infections. This study could help find a simpler way to manage HIV-1.